-
Innovation Ranking
NewInnovation Ranking – Aeglea BioTherapeutics Inc
Aeglea BioTherapeutics Inc (Aeglea) is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), is used for the treatment of arginase deficiency. It also develops AGLE-177, for treating classical homocystinuria, a rare disease cause due to hereditary genetic deficiency; AGLE-324, for treating cystinuria. Aeglea also provides enzyme solutions to treat diseases with unmet medical needs. The company works in partnership with research...
-
Product Insights
NewNet Present Value Model: Amgen Inc’s Aflibercept Biosimilar
Empower your strategies with our Net Present Value Model: Amgen Inc's Aflibercept Biosimilar report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Dazukibart
Empower your strategies with our Net Present Value Model: Pfizer Inc's Dazukibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Non-Small Cell Lung Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Non-Small Cell Lung Carcinoma Drug Details: XmAb-717 is under development for the treatment...
-
Product Insights
NewNet Present Value Model: Aeglea BioTherapeutics Inc’s Pegtarviliase
Empower your strategies with our Net Present Value Model: Aeglea BioTherapeutics Inc's Pegtarviliase report and make more profitable business decisions.Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Aeglea BioTherapeutics Inc's Pegtarviliase...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRTX-9768 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRTX-9768 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRTX-9768 in Solid Tumor Drug Details:MRTX-9768 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegtarviliase in Homocystinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegtarviliase in Homocystinuria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Pegtarviliase in HomocystinuriaDrug Details: AGLE-177 is under development for the treatment of homocystinuria including...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegzilarginase in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Pegzilarginase in Solid TumorDrug Details:Pegzilarginase (AEB-1102) (AERase) is under development for the treatment of arginase I...
-
Company Profile
Aeglea BioTherapeutics Inc – Company Profile
Spyre Therapeutics Inc (Spyre Therapeutics), formerly Aeglea BioTherapeutics Inc, is a clinical-stage biotechnology company. It develops and commercializes human enzymes for the treatment of enzyme therapeutics and rare metabolic diseases. The company’s program pipeline includes pegzilarginase, which is used for the treatment of arginase deficiency. Aeglea develops Pegtarviliase for treating classical homocystinuria, a rare disease caused due to hereditary genetic deficiency. The company also conducts preclinical programs for treating cystinuria and undisclosed rare diseases. It provides enzyme solutions to treat...
Add to Basket -
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...